NCT07405801
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07405801
Title A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Recruitment Not yet recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Hoffmann-La Roche
Indications
Therapies
Age Groups: senior
Covered Countries CAN

Facility Status City State Zip Country Details
McGill University Montreal Quebec H4A 3J1 Canada Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field